ArticleInternational ophthalmology2026
The effect of topical Ankaferd use on the recovery of wound healing in experimentally formed corneal perforations.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the clinical and histopathological outcomes of topical Ankaferd Blood Stopper (ABS) combined with autologous blood versus N-butyl-2-cyanoacrylate (NBCA) in the management of experimentally induced corneal perforations with tissue loss.
methodsThirty-four eyes of 29 New Zealand white rabbits were randomly assigned to four groups: ABS combined with autologous blood (n = 10), autologous blood alone (n = 9), NBCA (n = 10), and untreated controls (n = 5). A standardized 1-mm full-thickness central corneal perforation was created using a biopsy punch to simulate tissue loss. Clinical examinations were performed on postoperative days 1, 2, 3, 7, 14, and 21 to assess wound leakage, anterior chamber depth, corneal edema, and inflammation. On day 21, corneal transparency and histopathological findings (stromal fibrosis and inflammatory infiltration) were evaluated.
resultsDuring the first postoperative week, the ABS group showed significantly less wound leakage and anterior chamber shallowing compared to the other groups (p < 0.05). Adhesive dislodgement requiring reapplication was significantly more frequent in the NBCA group (p = 0.012). At the end of the follow-up (day 21), the ABS group demonstrated significantly better corneal transparency (p = 0.027). Histopathologically, stromal fibrosis and inflammatory cell infiltration were significantly reduced in the ABS-treated eyes (p < 0.05).
conclusionTopical ABS combined with autologous blood provides better clinical stability and more favorable biological healing than NBCA. These findings suggest that ABS may serve as a biologically advantageous alternative for the temporary management of corneal perforations.
Indexed as
Identifiers
42250026What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.